A majority of dealmakers say their companies are focused on defense or survival, but about a quarter are actively pursuing growth.
According to Mergermarket, the value of US M&A in the second quarter of 2020 was lower...more
The megadeals of 2019 may be off the table for now, but deal activity across healthcare and pharmaceuticals has proven resilient through the COVID-19 crisis -
Although pharma, medical and biotech (PMB) M&A deal value for...more